Cargando…

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

BACKGROUND: Class I histone deacetylases (HDACs) have been reported to be overexpressed in clear cell renal cell carcinoma (ccRCC), whereas the expression of class II HDACs is unknown. METHODS: Four isogenic cell lines C2/C2VHL and 786-O/786-OVHL with differential VHL expression are used in our stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramakrishnan, Swathi, Ku, ShengYu, Ciamporcero, Eric, Miles, Kiersten Marie, Attwood, Kris, Chintala, Sreenivasulu, Shen, Li, Ellis, Leigh, Sotomayor, Paula, Swetzig, Wendy, Huang, Ray, Conroy, Dylan, Orillion, Ashley, Das, Gokul, Pili, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977667/ https://www.ncbi.nlm.nih.gov/pubmed/27506904 http://dx.doi.org/10.1186/s12885-016-2604-7

Ejemplares similares

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015)

Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
por: Miles, Kiersten Marie, et al.
Publicado: (2014)

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer
por: Ellis, Leigh, et al.
Publicado: (2013)

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
por: Shen, Li, et al.
Publicado: (2012)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
por: Pili, Roberto, et al.
Publicado: (2017)

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression
por: Ellis, Leigh, et al.
Publicado: (2011)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
por: Chintala, Sreenivasulu, et al.
Publicado: (2012)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

Genomic profiling of collecting duct renal carcinoma
por: Chintala, Sreenivasulu, et al.
Publicado: (2016)

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
por: Rustum, Youcef M., et al.
Publicado: (2018)

Estrogen-Mediated Upregulation of Noxa Is Associated with Cell Cycle Progression in Estrogen Receptor-Positive Breast Cancer Cells
por: Liu, Wensheng, et al.
Publicado: (2011)

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
por: Kirk, Jason S., et al.
Publicado: (2014)

Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer
por: Fontana, Luigi, et al.
Publicado: (2013)

Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
por: Swetzig, Wendy M., et al.
Publicado: (2016)

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis
por: Ellis, Leigh, et al.
Publicado: (2014)

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation
por: Wang, Jianmin, et al.
Publicado: (2016)

NFX1, Its Isoforms and Roles in Biology, Disease and Cancer
por: Chintala, Sreenivasulu, et al.
Publicado: (2021)

Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition
por: Mae, Hirokazu, et al.
Publicado: (2023)

Cell death induced by HDACS inhibitors in ovarian cancer cell lines (serous and clear cells carcinomas) – role of NOTCH, TP53 and FN1
por: Silva, Fernanda, et al.
Publicado: (2010)

Post-Transcriptional Gene Regulation by HPV 16E6 and Its Host Protein Partners
por: Billingsley, Caylin L., et al.
Publicado: (2022)

Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
por: Yano, Mitsutake, et al.
Publicado: (2019)

CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma
por: Jiang, Nan, et al.
Publicado: (2020)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

A Cell-Based Screen Identifies HDAC Inhibitors as Activators of RIG-I Signaling
por: Fraile-Bethencourt, Eugenia, et al.
Publicado: (2022)

Genes Regulated by HPV 16 E6 and High Expression of NFX1-123 in Cervical Cancers
por: Chintala, Sreenivasulu, et al.
Publicado: (2020)

Transcription Repressor Protein ZBTB25 Associates with HDAC1-Sin3a Complex in Mycobacterium tuberculosis-Infected Macrophages, and Its Inhibition Clears Pathogen by Autophagy
por: Madhavan, Aravind, et al.
Publicado: (2021)

Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy
por: Ramakrishnan, Nithya, et al.
Publicado: (2016)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer
por: Lin, Ching-Ling, et al.
Publicado: (2019)

HDACs and the senescent phenotype of WI-38 cells
por: Place, Robert F, et al.
Publicado: (2005)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma
por: Kays, Joshua K., et al.
Publicado: (2020)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
por: Watanabe, Kazuhiro, et al.
Publicado: (2021)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
por: Doppalapudi, Sai Krishnaraya, et al.
Publicado: (2021)

A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2019)

Specific Control of Pancreatic Endocrine β- and δ-Cell Mass by Class IIa Histone Deacetylases HDAC4, HDAC5, and HDAC9
por: Lenoir, Olivia, et al.
Publicado: (2011)

Genome wide DNA methylation landscape reveals glioblastoma’s influence on epigenetic changes in tumor infiltrating CD4+ T cells
por: Bam, Marpe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ep0aekelvrbahkjv5jo783u8c4